In one of them, we treated the PBMCs and CMCs after three days for additional three days with the JAK inhibitor (JAKi) baricitinib, a small molecule used to treat patients with moderate to severe RA by inhibiting JAK1 and JAK2 as approved by the Food and Drug Administration (FDA).[22]. This evidence concerns the gene JAK1 and rheumatoid arthritis.